Bristol-Myers Squibb Company
COMBINATION THERAPY WITH ANTI-CD73 ANTIBODIES
Last updated:
Abstract:
Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-CD73 antibody in combination with an immuno-oncology agent, such as an anti-PD-1 antibody.
Status:
Application
Type:
Utility
Filling date:
3 Mar 2017
Issue date:
19 Sep 2019